Physician profile
Tryn Smith
NPI 1528829587
$754.15
in general payments reported to CMS, 2019-2025
13 companies · $754 in 2025
The $754 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.16 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $155.17 | 2025 | Erleada, Balversa, Rybrevant |
| Azurity Pharmaceuticals, INC. | $148.51 | 2025 | Danziten, Vivimusta |
| Genentech USA, INC. | $102.26 | 2025 | Tecentriq, Tecentriq Hybreza, Ocrevus Zunovo |
| Novartis Pharmaceuticals Corporation | $63.37 | 2025 | |
| Lilly USA, LLC | $53.98 | 2025 | Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $39.48 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $35.83 | 2025 | Eliquis |
| Jazz Pharmaceuticals INC. | $33.72 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.40 | 2025 | Alunbrig |
| Myriad Genetic Laboratories, INC. | $26.27 | 2025 | Myrisk |
| Recordati_rare_diseases_inc. | $23.68 | 2025 | Panhematin |
| Merck Sharp & Dohme LLC | $22.77 | 2025 | Keytruda, Keytruda Qlex |
| Puma Biotechnology, INC. | $19.71 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tryn Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.